A Phase 1 interventional study of Deupirfenidone and Pirfenidone (PFD) in Pharmacokinetic Analysis, sponsored by PureTech. Completed at 3 sites in United States. Open to participants aged 60 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by PureTech · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A three-part, randomized, double-blind study in healthy older adults to identify a dose of deupirfenidone for further clinical study.
A Phase 1 study to evaluate safety, tolerability, and PK in older healthy subjects of multiple twice daily (BID) or 3 times daily (TID) doses of deupirfenidone administered over 3 days compared to that of pirfenidone or placebo administered TID. The study also investigated the PK profile of deupirfenidone at steady state compared to that of pirfenidone at steady state and the effect of food on the PK profile of deupirfenidone and pirfenidone. The study was conducted in 3 parts. Part 1 was a randomized, double-blinded, two-period crossover study conducted in healthy older adults to evaluate the tolerability differentiation of BID dosing of deupirfenidone to pirfenidone. Part 2 was a randomized, double-blinded, two-period crossover study conducted in healthy older adults to evaluate the tolerability differentiation of TID dosing of deupirfenidone to pirfenidone. Part 3 was a randomized, double-blinded, parallel arm, placebo-controlled study conducted in healthy older adults to evaluate the safety and tolerability of two doses of deupirfenidone.
PureTech is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
deupirfenidone 850 mg BID
Drug: Deupirfenidone
pirfenidone 801 mg TID
Drug: Pirfenidone (PFD)
deupirfenidone 550 mg TID
Drug: Deupirfenidone
pirfenidone 801 mg TID
Drug: Pirfenidone (PFD)
deupirfenidone 550/824 mg TID
Drug: Deupirfenidone
placebo TID
Drug: Placebo
Swedish orange capsule
Also known as: LYT-100
Swedish orange capsule
Swedish orange capsule
Part 1: Cmax of BID deupirfenidone versus TID pirfenidone
To compare the Cmax of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered in a two-period crossover design.
Time frame: 14 days
Part 2: Cmax of TID deupirfenidone versus TID pirfenidone
To compare the Cmax of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered in a two-period crossover design.
Time frame: 14 days
Part 3: Cmax of TID deupirfenidone versus placebo
To evaluate the Cmax of two doses of deupirfenidone.
Time frame: 6 days
Part 1: AUC of BID deupirfenidone versus TID pirfenidone
To compare the AUC of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered in a two-period crossover design.
Time frame: 14 Days
Part 1: Tmax of BID deupirfenidone versus TID pirfenidone
To compare the Tmax of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered in a two-period crossover design.
Time frame: 14 Days
Part 2: AUC of TID deupirfenidone versus TID pirfenidone
To compare the AUC of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered in a two-period crossover design.
Time frame: 14 Days
Part 2: Tmax of TID deupirfenidone versus TID pirfenidone
To compare the Tmax of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered in a two-period crossover design.
Time frame: 14 Days
Part 3: AUC of TID deupirfenidone versus placebo
To evaluate the AUC of two doses of deupirfenidone.
Time frame: 6 Days
Part 3: PK profile of TID deupirfenidone versus placebo
To evaluate the Tmax of two doses of deupirfenidone.
Time frame: 6 Days
Part 1: The effect of food on the Cmax of BID deupirfenidone versus TID pirfenidone
To compare the Cmax of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.
Time frame: 1 day
Part 2: The effect of food on the Cmax of TID deupirfenidone versus TID pirfenidone
To compare the Cmax of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.
Time frame: 1 day
Part 1: The effect of food on the AUC of BID deupirfenidone versus TID pirfenidone
To compare the AUC of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.
Time frame: 6 Days
Part 1: The effect of food on the Tmax of BID deupirfenidone versus TID pirfenidone
To compare the Tmax of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.
Time frame: 1 Day
Part 2: The effect of food on the AUC of TID deupirfenidone versus TID pirfenidone
To compare the AUC of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.
Time frame: 1 Day
Part 2: The effect of food on the Tmax of TID deupirfenidone versus TID pirfenidone
To compare the Tmax of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.
Time frame: 1 Day
Plan to share: No — This was a pharmacokinetic study with no health-based outcomes.
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Jan 2022, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirfenidone
PureTech